ZYBT - שווי כולל של החברה jlzybio.com

Zhengye Biotechnology develops veterinary biopharmaceuticals, creating innovative vaccines to protect livestock in the PRC. The stock's price history on GURU.Markets shows an Enterprise Value of 53.66. The company relies on partnerships with agricultural holdings and clinics to implement diagnostics. Rising demand for biological products in Asia and collaboration with large-scale farms open significant prospects for expanding market share.

Enterprise Value determines the total acquisition price of an asset by summing market capitalization and net debt to eliminate the influence of financing structure. By analyzing the current enterprise value for Zhengye Biotechnology (ZYBT), an investor can correlate the total cost of acquiring the business with sustainable revenues from government livestock immunization programs, confirming the company's fundamental value.